GKT137831: Clinical Trials

5 trials of GKT137831, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 3 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Completed 3
Phase 12Completed 2

Follow GKT137831: new trials by email Literature Review of GKT137831 trials Research Report on GKT137831

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
Placebo Oral Tablet, GKT137831 - Idiopathic Pulmonary Fibrosis
Phase 2CompletedUniversity of Alabama at Birmingham582020-09-072026-05-11
Study to Evaluate the Pharmacokinetics and Drug-Drug Interactions of Setanaxib in Healthy Adult Male and Female Subjects
Setanaxib - Phase 1
Phase 1CompletedCalliditas Therapeutics AB642020-06-242022-06-30
Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets
GKT137831 - Phase 1
Phase 1CompletedCalliditas Therapeutics AB152018-12-192022-06-30
Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.
GKT137831, Placebo oral capsule - Primary Biliary Cirrhosis
Phase 2CompletedCalliditas Therapeutics AB1112017-06-262022-06-29
Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria
GKT137831, Placebo - Type 2 Diabetes Mellitus With Diabetic Nephropathy
Phase 2CompletedCalliditas Therapeutics AB1362013-10-012025-02-28

Conditions studied

Albuminuria (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Idiopathic Pulmonary Fibrosis (1)  ·  Liver Cirrhosis, Biliary (1)  ·  Proteinuria (1)

Sponsors

Calliditas Therapeutics AB (4)  ·  University of Alabama at Birmingham (1)

Countries

United States (3)  ·  Canada (2)  ·  France (2)  ·  Germany (2)  ·  Australia (1)  ·  Belgium (1)  ·  Czechia (1)  ·  Greece (1)  ·  Israel (1)  ·  Italy (1)  ·  Poland (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Philippe Wiesel, MD (2)  ·  Steven R Duncan, MD (1)

Results publications

PMID 33515429, PMID 36809195, PMID 37183520, PMID 41805697

NIH funding

2016 (1)